Keyphrases
TRPC6
100%
Chemotherapy-related Cardiomyopathy
100%
Heart Failure
100%
Chemotherapy
50%
Heart Cell
27%
Genetic Variants
22%
Cardioprotective Therapy
22%
Developing Heart
16%
Breast Cancer Patients
16%
Doxorubicin
16%
Chemotherapy-induced Heart Failure
16%
Female Mice
11%
Cumulative Dose
11%
Cardiomyopathy
11%
Patient's Will
11%
Cancer Patients
11%
Adverse Cardiac Events
11%
Arrhythmia
11%
Estrogen
11%
Risk Variant
11%
Mouse Model
11%
Care Plan
5%
Contractility
5%
Clinical Factors
5%
Blood Vessels
5%
Risk Genes
5%
Treatment Strategy
5%
Cardioprotection
5%
Patient Risk
5%
Cardiac Symptoms
5%
Lymphoma Patients
5%
Patients with Breast Cancer
5%
Women with Breast Cancer
5%
Young Women
5%
Breast Cancer
5%
Pediatric Research
5%
DNA Samples
5%
Postmenopausal Women
5%
Signaling Pathway
5%
High Risk
5%
Pediatric Lymphoma
5%
Genetic Differences
5%
High Dose
5%
Chemotherapy Treatment
5%
Genetic Studies
5%
Chemotherapy-induced Cardiotoxicity
5%
TRPC6 Channel
5%
Young Girls
5%
Surgical Removal
5%
Heart Rhythm
5%
Heart Arrhythmia
5%
Therapy-related
5%
Patient Experience
5%
Genetic mutation
5%
Breast Lymphoma
5%
Multiple Genes
5%
Patients with Heart Failure
5%
Older Women
5%
Lymphoma Cancer
5%
Cardiovascular Disease
5%
Cell-based
5%
Young children
5%
Medicine and Dentistry
TRPC6
100%
Congestive Heart Failure
50%
Cardiomyopathy
50%
Chemotherapy
50%
Heart Failure
50%
Myocardial Disease
50%
Isotopes of Calcium
31%
Breast Cancer
27%
Malignant Neoplasm
22%
Doxorubicin
13%
Cardiac Dysrhythmia
13%
Genetic Variability
11%
Side Effect
9%
Pediatrics
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Cardiomyopathy
50%
Heart Failure
50%
Myocardial Disease
50%
Congestive Heart Failure
50%
Breast Cancer
27%
Malignant Neoplasm
22%
Doxorubicin
13%
Heart Arrhythmia
13%
Mouse Model
9%
Side Effect
9%